TLC to Present at Upcoming Virtual Investor Conferences
TLC (NASDAQ: TLC, TWO: 4152), a clinical-stage pharmaceutical company, announced its participation in two upcoming virtual investor conferences. The HC Wainwright & Co Global Life Sciences Conference is scheduled for March 9-10, 2021, with on-demand presentations available from 7am ET on March 9. The Oppenheimer 31st Annual Healthcare Conference will take place on March 16-17, 2021, featuring a presentation on March 17 at 8am ET. TLC's corporate presentation will be accessible on their website.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company’s management team will be presenting at the following virtual investor conferences:
HC Wainwright & Co Global Life Sciences Conference (March 9-10, 2021)
Presentation: on-demand starting 7am ET, Tuesday, March 9, 2021
Oppenheimer 31st Annual Healthcare Conference (March 16-17, 2021)
Presentation: 8am ET, Wednesday, March 17, 2021
The management team will also be participating in one-on-one meetings during the conference. The corporate presentation will be available on the TLC website at www.tlcbio.com in the Investors section, under News & Events.
About TLC
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of a diverse, wholly owned portfolio of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLC’s annual report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLC’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.
FAQ
When is TLC presenting at the HC Wainwright & Co Global Life Sciences Conference?
What date will TLC present at the Oppenheimer 31st Annual Healthcare Conference?
Where can I find the TLC corporate presentation?
What type of company is TLC?
What technologies does TLC utilize in their drug delivery platform?
